October 2024

RHEUMATOLOGY

TREATING CONCURRENT PLAQUE PSORIASIS AND PSORIATIC ARTHRITIS

In this Medscape video, Eric Ruderman, MD, discusses challenges dermatologists and rheumatologists face in diagnosing and treating patients with concurrent skin and joint disease.

Dr. Ruderman highlights the importance of evaluation and therapeutic interventions to manage the progression of psoriatic arthritis (PsA), and he offers recommendations on managing concurrent plaque psoriasis (PsO) and PsA.

Learn more about the considerations and treatment for concurrent PsO and PsA.

Some patients with PsO will develop PsA. Typically, skin symptoms develop in advance of join involvement.

Potential indicators of PsA:
  • Stiffness and pain
  • Swelling of fingers and toes
  • Inflammation of tendons
  • Inflammation of the eyes

Not all therapies work equally well for both skin and joint disease. Identifying the aspects of the disease that are most problematic for the patient will help determine the treatment option that effectively addresses all their individual manifestations of psoriatic disease.
​
Treatment options could include:
  • Non-steroidal anti-inflammatory medications
  • Oral therapies
    • Methotrexate
    • Leflunomide
    • Apremilast
    • JAK inhibitors
  • TNF inhibitors
    • Adalimumab
    • Certolizumab
    • Golimumab
    • Infliximab
Newer biologic treatment options include:
  • IL-17 inhibitors
    • Secukinumab
    • Lxekizumab
    • Brodalumab
    • Bimekizumab
  • IL-12/23 inhibitor
    • Ustekinumab
Eric M. Ruderman, MD, Professor of Rheumatology at Northwestern Medicine

Refer a Patient

Northwestern Medicine welcomes the opportunity to partner with you in caring for your patients. ​

You May Also Like